Details for New Drug Application (NDA): 216109
✉ Email this page to a colleague
The generic ingredient in CEFAZOLIN SODIUM is cefazolin sodium. There are twenty-seven drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.
Summary for 216109
Tradename: | CEFAZOLIN SODIUM |
Applicant: | Hikma |
Ingredient: | cefazolin sodium |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 216109
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
CEFAZOLIN SODIUM | cefazolin sodium | POWDER;INTRAVENOUS | 216109 | NDA | Hikma Pharmaceuticals USA Inc. | 0143-9139 | 0143-9139-25 | 25 VIAL in 1 CARTON (0143-9139-25) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL |
CEFAZOLIN SODIUM | cefazolin sodium | POWDER;INTRAVENOUS | 216109 | NDA | Hikma Pharmaceuticals USA Inc. | 0143-9140 | 0143-9140-25 | 25 VIAL in 1 CARTON (0143-9140-25) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 2GM BASE/VIAL | ||||
Approval Date: | Oct 7, 2022 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 3GM BASE/VIAL | ||||
Approval Date: | Oct 7, 2022 | TE: | RLD: | Yes |
Complete Access Available with Subscription